14 completed, 2 active not recruiting, 1 recruiting, 1 unknown. 10 Phase 1, 7 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Active not recruiting 2 |
| Phase 3 | 7 | Completed 6, Unknown 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow EuBiologics Co.,Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children OSP:rTTHc CCV 25 ㎍ with Aluminum phosphate, OSP:rTTHc CCV 25 ㎍ without Aluminum phosphate, Euvichol®-Plus - Cholera Vaccination | Phase 2 | Recruiting | International Vaccine Institute | 390 | 2026-01-13 | 2026-04-03 |
| Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years EuHZV, Shingrix - Varicella Zoster Virus Infection, Herpes Zoster | Phase 1 | Active not recruiting | EuBiologics Co.,Ltd | 72 | 2024-07-15 | 2025-06-17 |
| Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years EuRSV, Placebo Comparator - Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV) | Phase 1 | Active not recruiting | EuBiologics Co.,Ltd | 100 | 2024-05-08 | 2025-06-15 |
| Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old EuNmCV-5, Menveo - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2023-02-28 | 2023-12-20 |
| Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults OSP:rTTHc Cholera Conjugate Vaccine Cohort A, OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A, Placebo Cohort A - Cholera Vaccination Reaction | Phase 1 | Completed | International Vaccine Institute | 150 | 2022-12-05 | 2025-03-25 |
| A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults EuCorVac-19, ChAdOx1 nCoV-19 - COVID-19 | Phase 3 | Completed | EuBiologics Co.,Ltd | 2600 | 2022-10-01 | 2024-06-17 |
| A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older EuCorVac-19, ChAdOx1 nCoV-19 - COVID-19 | Phase 3 | Completed | EuBiologics Co.,Ltd | 2852 | 2022-07-11 | 2025-01-07 |
| Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ Oral Cholera Vaccine Simplified (OCV-S), Shanchol™ - Cholera | Phase 3 | Completed | International Vaccine Institute | 2530 | 2021-10-06 | 2023-06-22 |
| Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults EuCorVac-19, Normal Saline - COVID-19 | Phase 1 / Phase 2 | Completed | EuBiologics Co.,Ltd | 279 | 2021-02-23 | 2023-05-19 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-09-01 | 2021-10-07 |
| Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines ATGC-100 100U, Botox 100U - Glabellar Frown Lines | Phase 3 | Completed | EuBiologics Co.,Ltd | 290 | 2020-06-29 | 2022-04-04 |
| Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults EuPCV15, Prevenar13 - Pneumococcal Disease | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-05-28 | 2021-10-07 |
| Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects ATGC-100, Botox® - Moderate to Severe Glabellar Lines | Phase 1 / Phase 2 | Completed | EuBiologics Co.,Ltd | 60 | 2019-04-19 | 2021-03-23 |
| Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults EuTCV, Typbar-TCV™, Typhim Vi® - Typhoid Fever | Phase 1 | Completed | EuBiologics Co.,Ltd | 75 | 2019-03-16 | 2019-12-09 |
| Safety and Immunogenicity of a New Formulation of Euvichol® Test Oral Cholera Vaccine, Euvichol® - Cholera | Phase 3 | Unknown | International Vaccine Institute | 442 | 2016-03-01 | 2015-12-17 |
| To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Euvichol, Shanchol - Prevention Harmful Effects | Phase 3 | Completed | EuBiologics Co.,Ltd | 3632 | 2014-05-01 | 2014-12-08 |
| To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men Euvichol - Prevention Harmful Effects | Phase 1 | Completed | EuBiologics Co.,Ltd | 20 | 2012-09-01 | 2013-02-20 |
COVID-19 (3) · Cholera (3) · Meningococcal Infections (2) · Typhoid Fever (2) · Chickenpox (1) · Herpes Zoster (1) · Pneumococcal Infections (1) · Respiratory Syncytial Virus Infections (1) · Varicella Zoster Virus Infection (1)
Botulinum Toxins, Type A (2) · ChAdOx1 nCoV-19 (2) · Meningococcal Vaccines (2) · Vaccines, Conjugate (2) · shanchol (2) · 13-valent pneumococcal vaccine (1) · Aluminum (1) · CCV protocol (1) · Cholera Vaccines (1) · Saline Solution (1) · Vi polysaccharide vaccine, typhoid (1) · aluminum phosphate (1)
South Korea (10) · Philippines (4) · Democratic Republic of the Congo (1) · Kenya (1) · Nepal (1)
Julia Lynch, MD (2) · Anh Wartel, MD (1) · Hong J Hee, Ph.D (1) · Laura Digilio, MD (1) · Roberto A. Espos, MD (1) · YJ Choi (1) · YJ Lee (1)
PMID 24753695, PMID 29895500, PMID 33849723, PMID 34050027, PMID 36447243, PMID 36774331, PMID 37783453, PMID 38614631, PMID 39112515, PMID 39217775, PMID 39318203, PMID 40872863